45,248 Shares in AngioDynamics, Inc. $ANGO Bought by Gallagher Fiduciary Advisors LLC

Gallagher Fiduciary Advisors LLC bought a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 45,248 shares of the medical instruments supplier’s stock, valued at approximately $589,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ANGO. Farther Finance Advisors LLC raised its position in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in AngioDynamics during the fourth quarter valued at about $27,000. State of Wyoming bought a new position in AngioDynamics during the second quarter valued at about $31,000. Legal & General Group Plc acquired a new position in AngioDynamics in the 2nd quarter valued at approximately $45,000. Finally, Russell Investments Group Ltd. raised its holdings in AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Price Performance

Shares of ANGO stock opened at $15.95 on Wednesday. The stock’s fifty day simple moving average is $14.11 and its 200 day simple moving average is $12.14. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29. The firm has a market cap of $659.21 million, a price-to-earnings ratio of -18.33 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ANGO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright increased their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Canaccord Genuity Group raised their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $19.50.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.00% of the stock is owned by company insiders.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.